HDL As a Contrast Agent for Medical Imaging

Overview

Journal Clin Lipidol

Date 2010 Mar 31

PMID 20352038

Citations 17

Authors

David P Cormode

Juan C Frias

Yanqing Ma

Wei Chen

Torjus Skajaa

Karen Briley-Saebo

Alessandra Barazza

Kevin Jon Williams

Willem Jm Mulder

Zahi A Fayad

Edward A Fisher

Affiliations

Soon will be listed here.

Abstract

Contrast-enhanced MRI of atherosclerosis can provide valuable additional information on a patient's disease state. As a result of the interactions of HDL with atherosclerotic plaque and the flexibility of its reconstitution, it is a versatile candidate for the delivery of contrast-generating materials to this pathogenic lesion. We herein discuss the reports of HDL modified with gadolinium to act as an MRI contrast agent for atherosclerosis. Furthermore, HDL has been modified with fluorophores and nanocrystals, allowing it to act as a contrast agent for fluorescent imaging techniques and for computed tomography. Such modified HDL has been found to be macrophage specific, and, therefore, can provide macrophage density information via noninvasive MRI. As such, modified HDL is currently a valuable contrast agent for probing preclinical atherosclerosis. Future developments may allow the application of this particle to further diseases and pathological or physiological processes in both preclinical models as well as in patients.

Citing Articles

Nanodiscs: A toolkit for membrane protein science.

Sligar S, Denisov I Protein Sci. 2020; 30(2):297-315.

PMID: 33165998 PMC: 7784751. DOI: 10.1002/pro.3994.

High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential.

Jomard A, Osto E Front Cardiovasc Med. 2020; 7:39.

PMID: 32296714 PMC: 7136892. DOI: 10.3389/fcvm.2020.00039.

Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research.

Kornmueller K, Vidakovic I, Prassl R Molecules. 2019; 24(15).

PMID: 31382521 PMC: 6695986. DOI: 10.3390/molecules24152829.

Core hydrophobicity tuning of a self-assembled particle results in efficient lipid reduction and favorable organ distribution.

Banik B, Wen R, Marrache S, Kumar A, Kolishetti N, Howerth E Nanoscale. 2017; 10(1):366-377.

PMID: 29218349 PMC: 5744677. DOI: 10.1039/c7nr06295h.

A facile method for isolation of recombinant human apolipoprotein A-I from E. coli.

Ikon N, Shearer J, Liu J, Tran J, Feng S, Kamei A Protein Expr Purif. 2017; 134:18-24.

PMID: 28336201 PMC: 5479713. DOI: 10.1016/j.pep.2017.03.015.

References

Jaffer F, Libby P, Weissleder R . Molecular imaging of cardiovascular disease. Circulation. 2007; 116(9):1052-61. DOI: 10.1161/CIRCULATIONAHA.106.647164. View

Anantharamaiah G, Jones J, Brouillette C, Schmidt C, Chung B, Hughes T . Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem. 1985; 260(18):10248-55. View

Tang C, Vaughan A, Anantharamaiah G, Oram J . Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1. J Lipid Res. 2005; 47(1):107-14. DOI: 10.1194/jlr.M500240-JLR200. View

Li H, Gray B, Corbin I, Lebherz C, Choi H, Lund-Katz S . MR and fluorescent imaging of low-density lipoprotein receptors. Acad Radiol. 2004; 11(11):1251-9. DOI: 10.1016/j.acra.2004.08.007. View

Nakashima Y, Plump A, Raines E, Breslow J, Ross R . ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994; 14(1):133-40. DOI: 10.1161/01.atv.14.1.133. View

Crich S, Lanzardo S, Alberti D, Belfiore S, Ciampa A, Giovenzana G . Magnetic resonance imaging detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low-density lipoprotein particles. Neoplasia. 2007; 9(12):1046-56. PMC: 2134901. DOI: 10.1593/neo.07682. View

Hainfeld J, Slatkin D, Focella T, Smilowitz H . Gold nanoparticles: a new X-ray contrast agent. Br J Radiol. 2006; 79(939):248-53. DOI: 10.1259/bjr/13169882. View

Frank P, Marcel Y . Apolipoprotein A-I: structure-function relationships. J Lipid Res. 2000; 41(6):853-72. View

Mitsumori L, Ricks J, Rosenfeld M, Schmiedl U, Yuan C . Development of a lipoprotein based molecular imaging MR contrast agent for the noninvasive detection of early atherosclerotic disease. Int J Cardiovasc Imaging. 2005; 20(6):561-7. DOI: 10.1007/s10554-004-7020-4. View

10.

Cormode D, Skajaa T, van Schooneveld M, Koole R, Jarzyna P, Lobatto M . Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett. 2008; 8(11):3715-23. PMC: 2629801. DOI: 10.1021/nl801958b. View

11.

Cormode D, Briley-Saebo K, Mulder W, Aguinaldo J, Barazza A, Ma Y . An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small. 2008; 4(9):1437-44. DOI: 10.1002/smll.200701285. View

12.

Rye K, Barter P . Antiinflammatory actions of HDL: a new insight. Arterioscler Thromb Vasc Biol. 2008; 28(11):1890-1. DOI: 10.1161/ATVBAHA.108.173575. View

13.

Rudd J, Myers K, Bansilal S, Machac J, Pinto C, Tong C . Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008; 49(6):871-8. DOI: 10.2967/jnumed.107.050294. View

14.

Frias J, Williams K, Fisher E, Fayad Z . Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc. 2004; 126(50):16316-7. DOI: 10.1021/ja044911a. View

15.

Navab M, Anantharamaiah G, Reddy S, Fogelman A . Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med. 2006; 3(10):540-7. DOI: 10.1038/ncpcardio0661. View

16.

Gianolio E, Giovenzana G, Longo D, Longo I, Menegotto I, Aime S . Relaxometric and modelling studies of the binding of a lipophilic Gd-AAZTA complex to fatted and defatted human serum albumin. Chemistry. 2007; 13(20):5785-97. DOI: 10.1002/chem.200601277. View

17.

Bulte J, Kraitchman D . Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004; 17(7):484-99. DOI: 10.1002/nbm.924. View

18.

Choudhury R, Fayad Z, Aguinaldo J, Itskovich V, Rong J, Fallon J . Serial, noninvasive, in vivo magnetic resonance microscopy detects the development of atherosclerosis in apolipoprotein E-deficient mice and its progression by arterial wall remodeling. J Magn Reson Imaging. 2003; 17(2):184-9. DOI: 10.1002/jmri.10246. View

19.

Corbin I, Li H, Chen J, Lund-Katz S, Zhou R, Glickson J . Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia. 2006; 8(6):488-98. PMC: 1601463. DOI: 10.1593/neo.05835. View

20.

Chen W, Vucic E, Leupold E, Mulder W, Cormode D, Briley-Saebo K . Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging. 2008; 3(6):233-42. DOI: 10.1002/cmmi.257. View